An immunohistochemical analysis to evaluate an inverse correlation between Runx2/Cbfa1 and NF kappa B in human osteosarcoma.
BACKGROUND
Dominant negative inhibition of nuclear factor kappa B (NF kappa B) signalling activity in a human osteosarcoma cell line (Saos2) results in malignant reversion and the induction of the osteoblast differentiating transcription factor, Runx2/Cbfa1. This observation suggests that there is an inverse relation between a transcription factor associated with malignant progression and chemoresistance (NF kappa B) and an osteoblast differentiating transcription factor (Runx2/Cbfa1).


OBJECTIVE
To assess and correlate Runx2/Cbfa1 and NF kappa B (p65) immunoreactivity in human osteosarcoma.


METHODS
Runx2/Cbfa1 and NFkappaB (p65) immunoreactivity was assessed on 11 paraffin wax embedded archival specimens of human primary osteosarcoma by standard immunohistochemical methods and scored on a scale of 0-3. A Pearson correlation analysis between Runx2/Cbfa1 and NF kappa B (p65) scores was established.


RESULTS
Runx2/Cbfa1 was expressed constitutively in all pathology specimens of human osteosarcoma. Of note, a chondroblastic osteosarcoma showed the highest Runx2/Cbfa1 immunoreactivity. A Pearson correlation did not support an inverse correlation between Runx2/Cbfa1 and NF kappa B (p65) scores (r = 0.57) in human osteosarcoma.


CONCLUSIONS
Runx2/Cbfa1 immunoreactivity does not inversely correlate with NF kappa B immunoreactivity, and thus cannot serve as an indirect measure of NF kappa B activity or an independent predictive or prognostic indicator.
Andela
V B
VB
The James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue Box 665, Rochester, NY 14642, USA. v_andela@yahoo.com
Siddiqui
F
F
Groman
A
A
Rosier
R N
RN
D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000378:metabolism* / Q000473:pathology; D050659:Core Binding Factor Alpha 1 Subunit; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D016328:NF-kappa B / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism; D012516:Osteosarcoma / Q000378:metabolism* / Q000473:pathology; D050656:Transcription Factor AP-2; D014157:Transcription Factors / Q000378:metabolism*
D014408:Biomarkers, Tumor; D050659:Core Binding Factor Alpha 1 Subunit; D004268:DNA-Binding Proteins; D016328:NF-kappa B; D009363:Neoplasm Proteins; C493709:RUNX2 protein, human; D050656:Transcription Factor AP-2; D014157:Transcription Factors
Cancer Res. 2000 Dec 1;60(23):6557-62
11118032
Mol Cell. 2001 Aug;8(2):303-16
11545733
Nature. 2001 Nov 1;414(6859):105-11
11689955
Dev Biol. 2002 May 1;245(1):95-108
11969258
Biochem Biophys Res Commun. 2002 Sep 20;297(2):237-41
12237108
Nat Med. 1999 Apr;5(4):412-7
10202930
Curr Opin Genet Dev. 2004 Feb;14(1):43-7
15108804
J Clin Oncol. 1994 Feb;12(2):423-31
8113851
Cell. 1997 May 30;89(5):747-54
9182762
J Surg Oncol. 1997 Jun;65(2):95-105
9209520
Cancer Res. 2003 Sep 1;63(17):5357-62
14500368